UBE2D4: A Potential Drug Target and Biomarker for the Treatment of Various Diseases

Target Name: UBE2D4

NCBI ID: G51619

UBE2D4

UBE2D4: A Potential Drug Target and Biomarker for the Treatment of Various Diseases

Introduction

Ubiquitin (UQ) is a protein that plays a critical role in the regulation of protein homeostasis, cell signaling, and DNA damage repair. It is a small protein that contains only 21 amino acid residues but has a significant impact on the stability and quality of Protein. UQ is covalently bound to a variety of protein lysine side chains, which provides it with a stable and negatively charged environment that can interact with other proteins. One of the unique features of UQ is its ability to carry a variety of different protein lysine modifications, including tyrosination, acetylation, and polyglutamylation. These modifications play important roles in regulating protein function and can modulate the stability, localization, and interactions of UQ.

UBE2D4, a Ubiquitin carrier protein D4, has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the biology of UBE2D4, its potential drug targets, and its potential as a biomarker for disease diagnosis and treatment.

Biography of UBE2D4

UBE2D4 is a 21 amino acid protein that contains a unique N-terminal region that is devoid of any conserved domains or features. It has a calculated molecular weight of 31 kDa and a pre-steady state G value of 76.9 kcal/mol. UBE2D4 is expressed in a variety of tissues and cells, including muscle, nerve, heart, and cancer cells. It is primarily localized to the cytoplasm and can also be found in the endoplasmic reticulum (ER) and the mitochondria.

UBE2D4 functions as a Ubiquitin carrier protein D4, which means it carries Ubiquitin modifications to other proteins. It has been shown that UBE2D4 can interact with a variety of different proteins, including histones, transcription factors, and signaling proteins. UBE2D4 can also modulate the stability and localization of these proteins, which can have a significant impact on their function and stability.

Potential Drug Targets

UBE2D4 has been identified as a potential drug target for the treatment of various diseases due to its unique ability to carry a variety of different protein lysine modifications. One of the main targets of UBE2D4 is the regulation of cell signaling pathways, which are involved in a wide range of physiological processes, including cell growth, differentiation, and apoptosis.

UBE2D4 has been shown to play a role in regulating the signaling pathway known as the T-cell signaling pathway. This pathway is involved in the regulation of cell growth, differentiation, and selection, and is a key factor in the development and progression of cancer . UBE2D4 has been shown to interact with the protein Ubiquitin E1 (UBE1) and regulate the Ubiquitinylation of UBE1. This interaction between UBE2D4 and UBE1 has been shown to play a role in the regulation of T-cell signaling pathway.

Another potential drug target for UBE2D4 is the regulation of the cytoskeleton. The cytoskeleton is a complex network of proteins that provide structural support to the cell and help maintain cell shape and stability. UBE2D4 has been shown to interact with the protein tubulin (MAPTATP2 ) and regulate the MAPTATP2-mediated cytoskeletal variability (

Protein Name: Ubiquitin Conjugating Enzyme E2 D4 (putative)

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, but may prefer 'Lys-11' and 'Lys-48'-linked polyubiquitination

The "UBE2D4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2D4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets